Prospective Multi-Institutional Observational Study of Brigatinib In ALK-rearranged advanced NSCLC, (ABRAID Study: WJOG11919L)
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ABRAID Study; WJOG11919L
- 11 Apr 2022 Planned End Date changed from 5 Jul 2025 to 5 Jul 2026.
- 28 Jul 2021 Planned End Date changed from 30 Jun 2025 to 5 Jul 2025.
- 20 Jul 2021 Planned End Date changed from 5 Jul 2025 to 30 Jun 2025.